Analysis | Samples | Factors | Units |
---|---|---|---|
Reversed phase NEGATIVE ION MODE | 05_FFA_D2O_BT474_GSK0001 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:1 nM GSK2194069 | AU |
Reversed phase NEGATIVE ION MODE | 12_FFA_D2O_BT474_GSK0001 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:1 nM GSK2194069 | AU |
Reversed phase NEGATIVE ION MODE | 19_FFA_D2O_BT474_GSK0001 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:1 nM GSK2194069 | AU |
Reversed phase NEGATIVE ION MODE | 08_FFA_D2O_BT474_Fasnall01 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:1 uM Fasnall | AU |
Reversed phase NEGATIVE ION MODE | 15_FFA_D2O_BT474_Fasnall01 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:1 uM Fasnall | AU |
Reversed phase NEGATIVE ION MODE | 22_FFA_D2O_BT474_Fasnall01 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:1 uM Fasnall | AU |
Reversed phase NEGATIVE ION MODE | 07_FFA_D2O_BT474_GSK1000 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:1 uM GSK2194069 | AU |
Reversed phase NEGATIVE ION MODE | 14_FFA_D2O_BT474_GSK1000 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:1 uM GSK2194069 | AU |
Reversed phase NEGATIVE ION MODE | 21_FFA_D2O_BT474_GSK1000 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:1 uM GSK2194069 | AU |
Reversed phase NEGATIVE ION MODE | 06_FFA_D2O_BT474_GSK0040 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:40 nM GSK2194069 | AU |
Reversed phase NEGATIVE ION MODE | 13_FFA_D2O_BT474_GSK0040 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:40 nM GSK2194069 | AU |
Reversed phase NEGATIVE ION MODE | 20_FFA_D2O_BT474_GSK0040 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:40 nM GSK2194069 | AU |
Reversed phase NEGATIVE ION MODE | 10_FFA_D2O_BT474_Fasnall40 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:40 uM Fasnall | AU |
Reversed phase NEGATIVE ION MODE | 17_FFA_D2O_BT474_Fasnall40 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:40 uM Fasnall | AU |
Reversed phase NEGATIVE ION MODE | 24_FFA_D2O_BT474_Fasnall40 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:40 uM Fasnall | AU |
Reversed phase NEGATIVE ION MODE | 09_FFA_D2O_BT474_Fasnall05 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:5 uM Fasnall | AU |
Reversed phase NEGATIVE ION MODE | 16_FFA_D2O_BT474_Fasnall05 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:5 uM Fasnall | AU |
Reversed phase NEGATIVE ION MODE | 23_FFA_D2O_BT474_Fasnall05 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:5 uM Fasnall | AU |
Reversed phase NEGATIVE ION MODE | 04_FFA_D2O_BT474_Control | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:Vehicle | AU |
Reversed phase NEGATIVE ION MODE | 11_FFA_D2O_BT474_Control | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:Vehicle | AU |
Reversed phase NEGATIVE ION MODE | 18_FFA_D2O_BT474_Control | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:Vehicle | AU |
Reversed phase NEGATIVE ION MODE | 01_FFA_Blank | Sample source:BT-474 cell lipid extract | Isotopic Tracer:NA | Drug Treatment:NA | AU |
Reversed phase NEGATIVE ION MODE | 02_FFA_Blank | Sample source:BT-474 cell lipid extract | Isotopic Tracer:NA | Drug Treatment:NA | AU |
Reversed phase NEGATIVE ION MODE | 03_FFA_Blank | Sample source:BT-474 cell lipid extract | Isotopic Tracer:NA | Drug Treatment:NA | AU |
Reversed phase NEGATIVE ION MODE | 25_FFA_Blank | Sample source:BT-474 cell lipid extract | Isotopic Tracer:NA | Drug Treatment:NA | AU |
Reversed phase NEGATIVE ION MODE | 26_FFA_Blank | Sample source:BT-474 cell lipid extract | Isotopic Tracer:NA | Drug Treatment:NA | AU |
Reversed phase NEGATIVE ION MODE | 27_FFA_Blank | Sample source:BT-474 cell lipid extract | Isotopic Tracer:NA | Drug Treatment:NA | AU |
Reversed phase POSITIVE ION MODE | 05_FFA_D2O_BT474_GSK0001 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:1 nM GSK2194069 | AU |
Reversed phase POSITIVE ION MODE | 12_FFA_D2O_BT474_GSK0001 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:1 nM GSK2194069 | AU |
Reversed phase POSITIVE ION MODE | 19_FFA_D2O_BT474_GSK0001 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:1 nM GSK2194069 | AU |
Reversed phase POSITIVE ION MODE | 08_FFA_D2O_BT474_Fasnall01 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:1 uM Fasnall | AU |
Reversed phase POSITIVE ION MODE | 15_FFA_D2O_BT474_Fasnall01 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:1 uM Fasnall | AU |
Reversed phase POSITIVE ION MODE | 22_FFA_D2O_BT474_Fasnall01 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:1 uM Fasnall | AU |
Reversed phase POSITIVE ION MODE | 07_FFA_D2O_BT474_GSK1000 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:1 uM GSK2194069 | AU |
Reversed phase POSITIVE ION MODE | 14_FFA_D2O_BT474_GSK1000 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:1 uM GSK2194069 | AU |
Reversed phase POSITIVE ION MODE | 21_FFA_D2O_BT474_GSK1000 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:1 uM GSK2194069 | AU |
Reversed phase POSITIVE ION MODE | 06_FFA_D2O_BT474_GSK0040 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:40 nM GSK2194069 | AU |
Reversed phase POSITIVE ION MODE | 13_FFA_D2O_BT474_GSK0040 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:40 nM GSK2194069 | AU |
Reversed phase POSITIVE ION MODE | 20_FFA_D2O_BT474_GSK0040 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:40 nM GSK2194069 | AU |
Reversed phase POSITIVE ION MODE | 10_FFA_D2O_BT474_Fasnall40 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:40 uM Fasnall | AU |
Reversed phase POSITIVE ION MODE | 17_FFA_D2O_BT474_Fasnall40 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:40 uM Fasnall | AU |
Reversed phase POSITIVE ION MODE | 24_FFA_D2O_BT474_Fasnall40 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:40 uM Fasnall | AU |
Reversed phase POSITIVE ION MODE | 09_FFA_D2O_BT474_Fasnall05 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:5 uM Fasnall | AU |
Reversed phase POSITIVE ION MODE | 16_FFA_D2O_BT474_Fasnall05 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:5 uM Fasnall | AU |
Reversed phase POSITIVE ION MODE | 23_FFA_D2O_BT474_Fasnall05 | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:5 uM Fasnall | AU |
Reversed phase POSITIVE ION MODE | 04_FFA_D2O_BT474_Control | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:Vehicle | AU |
Reversed phase POSITIVE ION MODE | 11_FFA_D2O_BT474_Control | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:Vehicle | AU |
Reversed phase POSITIVE ION MODE | 18_FFA_D2O_BT474_Control | Sample source:BT-474 cell lipid extract | Isotopic Tracer:20% D2O | Drug Treatment:Vehicle | AU |
Reversed phase POSITIVE ION MODE | 01_FFA_Blank | Sample source:BT-474 cell lipid extract | Isotopic Tracer:NA | Drug Treatment:NA | AU |
Reversed phase POSITIVE ION MODE | 02_FFA_Blank | Sample source:BT-474 cell lipid extract | Isotopic Tracer:NA | Drug Treatment:NA | AU |
Reversed phase POSITIVE ION MODE | 03_FFA_Blank | Sample source:BT-474 cell lipid extract | Isotopic Tracer:NA | Drug Treatment:NA | AU |
Reversed phase POSITIVE ION MODE | 25_FFA_Blank | Sample source:BT-474 cell lipid extract | Isotopic Tracer:NA | Drug Treatment:NA | AU |
Reversed phase POSITIVE ION MODE | 26_FFA_Blank | Sample source:BT-474 cell lipid extract | Isotopic Tracer:NA | Drug Treatment:NA | AU |
Reversed phase POSITIVE ION MODE | 27_FFA_Blank | Sample source:BT-474 cell lipid extract | Isotopic Tracer:NA | Drug Treatment:NA | AU |